As of November 6, 2026, Xeris Biopharma Holdings, Inc. has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 21, 2026 to November 2, 2026, naming 3 appointments and 1 departure. The latest filing names Menassie Taddese, appointed (Form 8-K, November 2, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Xeris Biopharma Holdings, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: In · Person: Menassie Taddese · Effective: 2026-11-02 · 8-K, 2026-11-02
- · In / out: In · Person: Nerissa Kreher · Effective: 2026-07-01 · 8-K, 2026-06-30
- · In / out: Out · Person: Jeffrey Sherman · Role: Director · 8-K, 2026-04-21
Xeris Biopharma Holdings, Inc. reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-21 to 2026-11-02. They name 3 people, with 3 appointments and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Xeris Biopharma Holdings, Inc. files it.
Also on the record for Xeris Biopharma Holdings, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 30, 2026 | Stake report, Schedule 13G/A, by Vanguard Capital Management | 4.98% of the class | 5%+ stakes | Source |
| July 31, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 5% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| January 30, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | 6.74% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Xeris Biopharma Holdings, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Xeris Biopharma Holdings, Inc. and the records around it.
Xeris Biopharma Holdings, Inc. elsewhere on the record
Companies that share a holder
- Vanguard Capital Management also filed stake reports on 1495 other companies: A10 Networks Inc (Oct 2026), Altisource Portfolio Solutions SA (Oct 2026), Alto Neuroscience Inc (Oct 2026)
- The Vanguard Group also filed stake reports on 2384 other companies: BellRing Brands, Inc. (Sep 2026), CAL-MAINE FOODS INC (Sep 2026), FTAI Aviation Ltd. (Sep 2026)
Watch Xeris Biopharma Holdings, Inc.
Get an email when Xeris Biopharma Holdings, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Xeris Biopharma Holdings, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Xeris Biopharma Holdings, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Xeris Biopharma Holdings, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-11-02 | In | 2026-11-02 | 8-K, 2026-11-02 | ||
| 2026-06-30 | In | 2026-07-01 | 8-K, 2026-06-30 | ||
| 2026-06-30 | In | Director | 8-K, 2026-06-30 | ||
| 2026-04-21 | Out | Director | 8-K, 2026-04-21 |
Who leads Xeris Biopharma Holdings, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Nerissa Kreher, appointed (filed 2026-06-30).
New leaders reset buying decisions — get the Full Report on Xeris Biopharma Holdings, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Xeris Biopharma Holdings, Inc., with the record behind each one.
Find candidates like Director at Xeris Biopharma Holdings, Inc.Every change, in the filing's words
Appointed: Menassie Taddese, effective 2026-11-02
Effective as of November 2, 2026 (the "Effective Date"), the Board of Directors (the "Board") of Xeris Biopharma Holdings, Inc. (the "Company") increased the size of the Board from eight (8) to nine (9) members, thereby creating a vacancy on the Board, and appointed Menassie Taddese to fill such vacancy.
- Mr. Taddese will serve as a Class II director and his term will expire at the Company's 2029 annual meeting of stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation, or removal.
- Mr. Taddese was also appointed to serve as a member of the Board's Audit Committee, effective as of the Effective Date.
- Mr. Taddese has served as a senior advisor at Emerging Markets Intelligence & Research ("EMIR"), an advisory and research firm based in Dubai, United Arab Emirates, since March 2023.
- He previously served as President, Emerging Markets at Viatris Inc. ("Viatris"), a global healthcare company, from November 2020 to December 2022.
- Prior to Viatris, Mr. Taddese held various positions of increasing responsibility at Pfizer Inc. from June 1997 to November 2020, including in corporate and treasury functions and in senior finance, commercial and general management roles.
- Mr. Taddese currently serves on the board of directors of Medexus Pharmaceuticals Inc., a specialty pharmaceutical company listed on the Toronto Stock Exchange, where he chairs the audit committee.
- He is also a member of the Business Council for International Understanding.
Appointed: Nerissa Kreher, effective 2026-07-01
On June 29, 2026, the Board of Directors (the "Board") of Xeris Biopharma Holdings, Inc. (the "Company") increased the size of the Board from seven (7) to eight (8) members, thereby creating a vacancy on the Board, and appointed Nerissa Kreher, M.D., to fill such vacancy, effective as of July 1, 2026.
Appointed: Nerissa Kreher, Director
Dr. Kreher will serve as a Class III director and her term will expire at the Company's 2027 annual meeting of stockholders, or until her earlier death, resignation, or removal.
- Dr. Kreher has not been appointed to any committees of the Board at this time.
- Since January 2025, Dr. Kreher has served as Chief Medical Officer of Alltrna, an RNA (tRNA) platform company.
- Additionally, since July 2024, she has served as the Founder of Mountainview Clinical Development Consulting, a specialized advisory firm, where she provides fractional clinical development, medical affairs, and regulatory strategy services to early-stage biotech and life sciences companies.
- From March 2024 to December 2024, Dr. Kreher served as an interim Chief Medical Officer for Lucy Therapeutics and also was a clinical development consultant for several rare disease biotechnology companies.
- Prior to that, she served as Chief Medical Officer of Entrada Therapeutics, a publicly traded biotechnology company, from December 2020 to February 2024.
- She also held Chief Medical Officer roles at Tiburio Therapeutics (from March 2019 to December 2020) and AVROBIO (acquired by Tectonic Therapeutics) (from October 2016 to December 2018), where she oversaw clinical development for multiple gene therapy programs.
- Earlier in her career, she served as Global Head (VP) of Clinical and Medical Affairs at Zafgen (from March 2015 to July 2016) and held key roles at Shire (from April 2013 to March 2015) and Enobia Pharma (January 2011 until its acquisition by Alexion Pharmaceuticals in 2012).
Departing: Jeffrey Sherman, Director
On April 20, 2026, Dr. Jeffrey Sherman, a member of the Board of Directors (the "Board") of Xeris Biopharma Holdings, Inc. (the "Company"), provided notice to the Company of his decision to retire from the Board and not stand for reelection at the Company's 2026 Annual Meeting of Stockholders (the "2026 Annual Meeting").
- Dr. Sherman has served as a director of the Company since 2021 and is a member of the Compensation Committee and Nominating and Corporate Governance Committee.
- Dr. Sherman will continue to serve in such roles until his term as director expires at the 2026 Annual Meeting.
- In connection with Dr. Sherman's retirement, the Board has approved a reduction in the size of the Board from eight to seven directors, effective as of the expiration of Dr. Sherman's term at the 2026 Annual Meeting.
- Dr. Sherman's decision to retire and not to stand for reelection was not because of any disagreement with the Company or its management on any matter relating to the Company's operations, policies, or practices.
- The Board thanks Dr. Sherman for his years of service, dedication to the Board, and his many contributions to the Company.
Tools for this story
Each opens in a new tab, filled in for Xeris Biopharma Holdings, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.